Browsing by Author "Hagemann J."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus
    (John Wiley and Sons Inc, 2021) Hagemann J.; Onorato G.L.; Jutel M.; Akdis C.A.; Agache I.; Zuberbier T.; Czarlewski W.; Mullol J.; Bedbrook A.; Bachert C.; Bennoor K.S.; Bergmann K.-C.; Braido F.; Camargos P.; Caraballo L.; Cardona V.; Casale T.; Cecchi L.; Chivato T.; Chu D.K.; Cingi C.; Correia-de-Sousa J.; del Giacco S.; Dokic D.; Dykewicz M.; Ebisawa M.; El-Gamal Y.; Emuzyte R.; Fauquert J.-L.; Fiocchi A.; Fokkens W.J.; Fonseca J.A.; Gemicioglu B.; Gomez R.-M.; Gotua M.; Haahtela T.; Hamelmann E.; Iinuma T.; Ivancevich J.C.; Jassem E.; Kalayci O.; Kardas P.; Khaitov M.; Kuna P.; Kvedariene V.; Larenas-Linnemann D.E.; Lipworth B.; Makris M.; Maspero J.F.; Miculinic N.; Mihaltan F.; Mohammad Y.; Montefort S.; Morais-Almeida M.; Mösges R.; Naclerio R.; Neffen H.; Niedoszytko M.; O’Hehir R.E.; Ohta K.; Okamoto Y.; Okubo K.; Panzner P.; Papadopoulos N.G.; Passalacqua G.; Patella V.; Pereira A.; Pfaar O.; Plavec D.; Popov T.A.; Prokopakis E.P.; Puggioni F.; Raciborski F.; Reijula J.; Regateiro F.S.; Reitsma S.; Romano A.; Rosario N.; Rottem M.; Ryan D.; Samolinski B.; Sastre J.; Solé D.; Sova M.; Stellato C.; Suppli-Ulrik C.; Tsiligianni I.; Valero A.; Valiulis A.; Valovirta E.; Vasankari T.; Ventura M.T.; Wallace D.; Wang D.Y.; Williams S.; Yorgancioglu A.; Yusuf O.M.; Zernotti M.; Bousquet J.; Klimek L.
    Background: Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods: A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results: Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p <.001). Conclusions: This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire. © 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
    (John Wiley and Sons Inc, 2023) Bousquet J.; Melén E.; Haahtela T.; Koppelman G.H.; Togias A.; Valenta R.; Akdis C.A.; Czarlewski W.; Rothenberg M.; Valiulis A.; Wickman M.; Akdis M.; Aguilar D.; Bedbrook A.; Bindslev-Jensen C.; Bosnic-Anticevich S.; Boulet L.P.; Brightling C.E.; Brussino L.; Burte E.; Bustamante M.; Canonica G.W.; Cecchi L.; Celedon J.C.; Chaves Loureiro C.; Costa E.; Cruz A.A.; Erhola M.; Gemicioglu B.; Fokkens W.J.; Garcia-Aymerich J.; Guerra S.; Heinrich J.; Ivancevich J.C.; Keil T.; Klimek L.; Kuna P.; Kupczyk M.; Kvedariene V.; Larenas-Linnemann D.E.; Lemonnier N.; Lodrup Carlsen K.C.; Louis R.; Makela M.; Makris M.; Maurer M.; Momas I.; Morais-Almeida M.; Mullol J.; Naclerio R.N.; Nadeau K.; Nadif R.; Niedoszytko M.; Okamoto Y.; Ollert M.; Papadopoulos N.G.; Passalacqua G.; Patella V.; Pawankar R.; Pham-Thi N.; Pfaar O.; Regateiro F.S.; Ring J.; Rouadi P.W.; Samolinski B.; Sastre J.; Savouré M.; Scichilone N.; Shamji M.H.; Sheikh A.; Siroux V.; Sousa-Pinto B.; Standl M.; Sunyer J.; Taborda-Barata L.; Toppila-Salmi S.; Torres M.J.; Tsiligianni I.; Valovirta E.; Vandenplas O.; Ventura M.T.; Weiss S.; Yorgancioglu A.; Zhang L.; Abdul Latiff A.H.; Aberer W.; Agache I.; Al-Ahmad M.; Alobid I.; Ansotegui I.J.; Arshad S.H.; Asayag E.; Barbara C.; Baharudin A.; Battur L.; Bennoor K.S.; Berghea E.C.; Bergmann K.C.; Bernstein D.; Bewick M.; Blain H.; Bonini M.; Braido F.; Buhl R.; Bumbacea R.S.; Bush A.; Calderon M.; Calvo-Gil M.; Camargos P.; Caraballo L.; Cardona V.; Carr W.; Carreiro-Martins P.; Casale T.; Cepeda Sarabia A.M.; Chandrasekharan R.; Charpin D.; Chen Y.Z.; Cherrez-Ojeda I.; Chivato T.; Chkhartishvili E.; Christoff G.; Chu D.K.; Cingi C.; Correia de Sousa J.; Corrigan C.; Custovic A.; D’Amato G.; Del Giacco S.; De Blay F.; Devillier P.; Didier A.; do Ceu Teixeira M.; Dokic D.; Douagui H.; Doulaptsi M.; Durham S.; Dykewicz M.; Eiwegger T.; El-Sayed Z.A.; Emuzyte R.; Fiocchi A.; Fyhrquist N.; Gomez R.M.; Gotua M.; Guzman M.A.; Hagemann J.; Hamamah S.; Halken S.; Halpin D.M.G.; Hofmann M.; Hossny E.; Hrubiško M.; Irani C.; Ispayeva Z.; Jares E.; Jartti T.; Jassem E.; Julge K.; Just J.; Jutel M.; Kaidashev I.; Kalayci O.; Kalyoncu A.F.; Kardas P.; Kirenga B.; Kraxner H.; Kull I.; Kulus M.; La Grutta S.; Lau S.; Le Tuyet Thi L.; Levin M.; Lipworth B.; Lourenço O.; Mahboub B.; Martinez-Infante E.; Matricardi P.; Miculinic N.; Migueres N.; Mihaltan F.; Mohammad Y.; Moniuszko M.; Montefort S.; Neffen H.; Nekam K.; Nunes E.; Nyembue Tshipukane D.; O’Hehir R.; Ogulur I.; Ohta K.; Okubo K.; Ouedraogo S.; Olze H.; Pali-Schöll I.; Palomares O.; Palosuo K.; Panaitescu C.; Panzner P.; Park H.S.; Pitsios C.; Plavec D.; Popov T.A.; Puggioni F.; Quirce S.; Recto M.; Repka-Ramirez M.S.; Robalo Cordeiro C.; Roche N.; Rodriguez-Gonzalez M.; Romantowski J.; Rosario Filho N.; Rottem M.; Sagara H.; Serpa F.S.; Sayah Z.; Scheire S.; Schmid-Grendelmeier P.; Sisul J.C.; Sole D.; Soto-Martinez M.; Sova M.; Sperl A.; Spranger O.; Stelmach R.; Suppli Ulrik C.; Thomas M.; To T.; Todo-Bom A.; Tomazic P.V.; Urrutia-Pereira M.; Valentin-Rostan M.; Van Ganse E.; van Hage M.; Vasankari T.; Vichyanond P.; Viegi G.; Wallace D.; Wang D.Y.; Williams S.; Worm M.; Yiallouros P.; Yusuf O.; Zaitoun F.; Zernotti M.; Zidarn M.; Zuberbier J.; Fonseca J.A.; Zuberbier T.; Anto J.M.
    Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases. © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air® approach
    (John Wiley and Sons Inc, 2023) Bousquet J.; Anto J.M.; Sousa-Pinto B.; Czarlewski W.; Bedbrook A.; Haahtela T.; Klimek L.; Pfaar O.; Kuna P.; Kupczyk M.; Regateiro F.S.; Samolinski B.; Valiulis A.; Yorgancioglu A.; Arnavielhe S.; Basagaña X.; Bergmann K.C.; Bosnic-Anticevich S.; Brussino L.; Canonica G.W.; Cardona V.; Cecchi L.; Chaves-Loureiro C.; Costa E.; Cruz A.A.; Gemicioglu B.; Fokkens W.J.; Ivancevich J.C.; Kraxner H.; Kvedariene V.; Larenas-Linnemann D.E.; Laune D.; Louis R.; Makris M.; Maurer M.; Melén E.; Micheli Y.; Morais-Almeida M.; Mullol J.; Niedoszytko M.; Okamoto Y.; Papadopoulos N.G.; Patella V.; Pham-Thi N.; Rouadi P.W.; Sastre J.; Scichilone N.; Sheikh A.; Sofiev M.; Taborda-Barata L.; Toppila-Salmi S.; Tsiligianni I.; Valovirta E.; Ventura M.T.; Vieira R.J.; Zidarn M.; Amaral R.; Ansotegui I.J.; Bédard A.; Benveniste S.; Bewick M.; Bindslev-Jensen C.; Blain H.; Bonini M.; Bourret R.; Braido F.; Carreiro-Martins P.; Charpin D.; Cherrez-Ojeda I.; Chivato T.; Chu D.K.; Cingi C.; Del Giacco S.; de Blay F.; Devillier P.; De Vries G.; Doulaptsi M.; Doyen V.; Dray G.; Fontaine J.-F.; Gomez R.M.; Hagemann J.; Heffler E.; Hofmann M.; Jassem E.; Jutel M.; Keil T.; Kritikos V.; Kull I.; Kulus M.; Lourenço O.; Mathieu-Dupas E.; Menditto E.; Mösges R.; Murray R.; Nadif R.; Neffen H.; Nicola S.; O’Hehir R.; Olze H.; Palamarchuk Y.; Pépin J.-L.; Pétré B.; Picard R.; Pitsios C.; Puggioni F.; Quirce S.; Raciborski F.; Reitsma S.; Roche N.; Rodriguez-Gonzalez M.; Romantowski J.; Sá-Sousa A.; Serpa F.S.; Savouré M.; Shamji M.H.; Sova M.; Sperl A.; Stellato C.; Todo-Bom A.; Tomazic P.V.; Vandenplas O.; Van Eerd M.; Vasankari T.; Viart F.; Waserman S.; Fonseca J.A.; Zuberbier T.
    MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma. © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.